Gene · 1828
Papers3,287
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
321 to 340 of 3,287
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Natural Retinol Analogs Potentiate the Effects of Retinal on Aged and Photodamaged Skin: Results from In Vitro to Clinical Studies. | Dermatol Ther (Heidelb) | 2023 | 37615835 | PubTator, text mining | PubMed |
| Emergence and influence of sequence bias in evolutionarily malleable, mammalian tandem arrays. | BMC Biol | 2023 | 37612705 | PubTator, text mining | PubMed |
| Recurrent staphylococcal scalded skin syndrome in a 20-month old-A case report. | Clin Case Rep | 2023 | 37601422 | PubTator, text mining | PubMed |
| Spatial transcriptomics reveals distinct and conserved tumor core and edge architectures that predict survival and targeted therapy response. | Nat Commun | 2023 | 37596273 | PubTator, text mining | PubMed |
| Prevalence of immune mediated vesiculobullous lesions among patients visiting a private dental hospital with special emphasis on gingival manifestation. | J Indian Soc Periodontol | 2023 | 37593559 | PubTator, text mining | PubMed |
| Correlation of desmoglein 1 and 3 immunohistochemistry with autoantibody levels and clinical severity in pemphigus. | J Cutan Pathol | 2023 | 37584110 | PubTator, text mining | PubMed |
| Dupilumab effectively and rapidly treats bullous pemphigoid by inhibiting the activities of multiple cell types. | Front Immunol | 2023 | 37575240 | PubTator, text mining | PubMed |
| The landscape of the immunoglobulin repertoire in endemic pemphigus foliaceus. | Front Immunol | 2023 | 37575223 | PubTator, text mining | PubMed |
| Interruption of p53-MDM2 Interaction by Nutlin-3a in Human Lymphoma Cell Models Initiates a Cell-Dependent Global Effect on Transcriptome and Proteome Level. | Cancers (Basel) | 2023 | 37568720 | PubTator, text mining | PubMed |
| Targeting Th17 cells: a promising strategy to treat oral mucosal inflammatory diseases. | Front Immunol | 2023 | 37564654 | PubTator, text mining | PubMed |
| Immunotherapies in MuSK-positive Myasthenia Gravis; an IgG4 antibody-mediated disease. | Front Immunol | 2023 | 37564637 | PubTator, text mining | PubMed |
| Targeting SERCA2 in organotypic epidermis reveals MEK inhibition as a therapeutic strategy for Darier disease. | JCI Insight | 2023 | 37561594 | PubTator, text mining | PubMed |
| Genetic Correlations Among Corneal Biophysical Parameters and Anthropometric Traits. | Transl Vis Sci Technol | 2023 | 37561511 | PubTator, text mining | PubMed |
| Juvenile Pemphigus Foliaceus in a Patient With Psoriasis Receiving Narrow-Band Ultraviolet-B: Successful Treatment With Rituximab. | J Drugs Dermatol | 2023 | 37556511 | PubTator, text mining | PubMed |
| Case report: a successful treatment with immune checkpoint inhibitors was associated with severe dermatologic toxicities in a patient with double primary malignancies. | Discov Oncol | 2023 | 37553451 | PubTator, text mining | PubMed |
| Autoimmune bullous dermatoses in cancer patients treated by immunotherapy: a literature review and Italian multicentric experience. | Front Med (Lausanne) | 2023 | 37547602 | PubTator, text mining | PubMed |
| Role of Cutaneous Microbiome in Dermatology. | Indian J Dermatol | 2023 | 37529462 | PubTator, text mining | PubMed |
| HLA class II antigens in Croatian patients with pemphigus vulgaris and their correlation with anti-desmoglein antibodies. | Front Immunol | 2023 | 37529044 | PubTator, text mining | PubMed |
| Rare Cutaneous Side Effects of Imiquimod: A Review on Its Mechanisms, Diagnosis, and Management. | Dermatol Ther (Heidelb) | 2023 | 37528289 | PubTator, text mining | PubMed |
| Validated graft-specific biomarkers identify patients at risk for chronic graft-versus-host disease and death. | J Clin Invest | 2023 | 37526081 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/1828/papers?page=17